Question-and-Answer Session
Operator
(Operator instructions). Our first question comes from the line of Charles Duncan from JPM Securities. Please proceed.
Charles Duncan - JPM Securities
I had a question regarding the schizophrenia disease and adjunctive therapy trial you mentioned Uli that that might be the quickest route to the market, I am wondering if you could expound on that and really kind of compare and contrast that to the other programs that you have ongoing and what gives you confidence that could be first.
Dr. Uli Hacksell
Well there are multiple reasons for that hypothesis, one of them is that we have conducted several schizophrenia trials, similar to the ones that we believe that Biovail will conduct here and we know that is pretty straight forward to recruit patients, there are many patients available, in schizophrenia research.
And we have our previous time lines that we used in our previous studies to try to get a brief on how long it takes to conduct the schizophrenia study. We know also by experience that PDP studies are slower than schizophrenia studies, we expect and I had mentioned that ADP also may be faster than PDPs studies simply because of the larger availability of ADP patients.
Charles Duncan - JPM Securities
Okay and then with regard to the measurement of efficacy in those trials, do you intend to use a central reviewer mechanism and how might you limit the impact on those trials or the Parkinson's trials of geography effect?
Dr. Uli Hacksell
Roger may be you can answer that.
Dr. Roger Mills
Sure. So the schizophrenia would be assessed using the trial. There is a difference with schizophrenia to the Parkinson's studies and as much as the investigator of basic schizophrenia studies or psychiatrists they are used to administering that the various psychiatric scales. But obviously in PDP, the SAP or the psychiatric scale which were the investigators are essentially neurologists. As of the central rating was clearly applicable in PDP due to the fact that many of the investigators weren't as comfortable perhaps a psychiatrist might have been using psychiatric scales. With ADP we haven't said what the end point of that study will be yet and we haven't finally defined that. However it is likely to be a scale which is commonly used in the assessment of Alzheimer's patients and is likely to be very well validated in the investigations that we will be using, we will be comfortable using that scale.
- To read the full transcript on Seeking Alpha, click here »
